Prasad Raju 4
4 · CRISPR Therapeutics AG · Filed Mar 18, 2025
Insider Transaction Report
Form 4
Prasad Raju
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-03-14−10,000→ 20,000 total→ Common Shares (10,000 underlying) - Sale
Common Shares
2025-03-17$41.80/sh−3,762$157,252→ 12,714 total - Exercise/Conversion
Common Shares
2025-03-14+10,000→ 16,476 total - Award
Stock Option (Right to Buy)
2025-03-14+36,666→ 36,666 totalExercise: $42.12Exp: 2035-03-14→ Common Shares (36,666 underlying) - Award
Restricted Stock Units
2025-03-14+27,500→ 27,500 total→ Common Shares (27,500 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.
- [F4]This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
- [F5]This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.